Savara stock plummets 75% after drug study fails to hit target MarketWatch By John Harbison|2019-06-25T10:16:08-08:00June 12, 2019|Tech Coast Angels Portfolio Companies in the Press|Comments Off on Savara stock plummets 75% after drug study fails to hit target Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkXingEmail About the Author: John Harbison Related Posts
